Articles tagged with Flu Vaccines
Researchers identified molecular signatures that predict immune protection in response to flu vaccination, with elderly individuals showing high levels of monocytes and low antibody-producing B cells. This study provides insight into potential mechanisms underlying reduced vaccine efficacy in older adults.
A York University study found that vaccination strategies should be adjusted based on region-specific characteristics, such as age demographics and virus transmission rates. Early vaccination leads to better public health outcomes, including reduced infection rates, hospitalizations, and stress on healthcare systems.
A prime-boost H7N9 influenza vaccine concept has shown promising results in a small clinical trial, demonstrating the potential for a single dose to provide protection. The vaccine, which combines a live but weakened virus with an inactivated booster, elicited a robust immune response in both young and older adults.
A recent survey found that only 42.7% of US hospitals require flu vaccination for all healthcare providers, leaving many staff members unprotected against the virus. This poses a significant risk to patients, particularly those with weakened immune systems.
Researchers developed a simple method to track and predict viral evolution based on whole-genome sequences of influenza viruses. By identifying genetic variants that change the structure of influenza proteins, they found that many strains used in vaccines during previous seasons lacked these markers.
Yale researchers developed a high-dose flu vaccine strategy that lowered infection rates by 64% among patients with immune system cancers. The novel dosing schedule improved protection against all flu strains in 66% of patients, offering promising results for cancer patient populations.
Researchers created a machine learning framework that predicts vaccine efficacy on an individual basis using genetic signatures. The framework demonstrated high accuracy in predicting yellow fever and flu vaccine responses.
Researchers found that statins may hinder immune response to flu vaccine and lower vaccine effectiveness in older adults, suggesting potential implications for flu vaccine recommendations and guidelines. The studies analyzed data from nearly 7,000 adults over 65 in four countries, including the US.
Australian researchers have found a way to boost influenza A vaccine effectiveness by adding an adjuvant, which stimulates both innate and adaptive immunity. The additive provides cross-protective capabilities, reducing the ability of the virus to infect cells and spread.
A new study published in JAMA found that flu vaccination can prevent up to 57% of hospitalizations due to influenza pneumonia. The research used data from over 2,700 patients and showed that the vaccine not only prevents symptoms but also serious complications like pneumonia requiring hospitalization.
Research suggests extending flu vaccine administration to 5-16 year old children is the most cost-effective option, reducing disease burden in the general population. Universal vaccination of all low-risk individuals over 2 years could achieve the highest net benefit.
A new study found that high-dose flu shots significantly reduced hospitalizations among older nursing home residents during the influenza season. The study showed a 1.2% difference in admission rates between those who received high-dose vaccine and standard dose vaccine, resulting in thousands fewer hospitalizations.
A study published in JAMA found that more than half of hospitalizations due to influenza pneumonia could be prevented by influenza vaccination. The study used data from 2,767 patients hospitalized with community-acquired pneumonia during three consecutive influenza seasons.
A study published in JAMA found that patients with influenza-associated pneumonia are less likely to have received a flu vaccination compared to those with non-influenza pneumonia. The study estimated a 57% lower odds ratio of vaccination among cases hospitalized with influenza-associated pneumonia.
A study found that counties with higher flu vaccination rates among adults under 65 had a 21% lower chance of elderly adults being diagnosed with flu-related illness. Community-wide vaccination may boost protection provided by individual vaccination.
A study of over 1 million Medicare recipients found that flu vaccines with a high match rate to the prevalent strain reduced pneumonia hospitalizations by 4.2% and deaths by 2.0%. The study estimated lives saved and prevented hospitalizations annually in long-stay nursing home residents.
Researchers at the University of Wisconsin-Madison have developed a new method for making flu vaccines using cell culture, which could lead to faster and more efficient vaccine production. This technology could potentially replace traditional egg-based vaccine production methods, which are limited by avian influenza outbreaks.
Researchers have made a major advance toward creating an effective, long-lasting flu vaccine by inducing broadly neutralizing antibodies in animal models. The study's findings show that the vaccine candidate can produce powerful 'broadly neutralizing antibodies' against many influenza subtypes.
A recent study found that influenza vaccines offer moderate, sustained protection up to 6 months post-vaccination, suggesting yearly vaccination may be prudent. Administering vaccines early in the fall can still prevent the greatest number of infections.
A new Brown University study analyzed nursing home records to show that flu vaccinations significantly reduce deaths and hospitalizations among the elderly. The study found a 50-percentage point increase in match rate for A/H3N2 strain resulted in saving 2,560 lives and preventing 3,200 hospitalizations.
Johns Hopkins researchers study nasal spray flu vaccine in human nasal tract cells to determine optimal weakening or strengthening of the virus. They find that by adjusting nine mutations, a stronger vaccine can be created for older adults while still protecting children under two, offering new hope for effective flu vaccines.
A new virus-like particle vaccine has been developed to protect against a wide variety of influenza viruses. The vaccine was shown to provide significant protection against many different flu strains, including avian H5N1 and H7N9 viruses, which have caused many human cases and deaths in recent years.
Researchers create a virus-like particle vaccine cocktail that expresses different subtypes of the hemagglutinin protein, providing cross-protective immunity against multiple subtypes. The study shows that 95% of mice vaccinated with the investigational cocktail were protected against eight different influenza strains.
A phase 2 trial found that AS03 and MF59 adjuvants increased immune responses to an inactivated H7N9 influenza vaccine, with AS03-adjuvanted formulations inducing the highest antibody response. The study suggests AS03 as a first-line adjuvant for H7N9 vaccines in adults.
A new vaccine patch made of dissolvable material has been shown to be effective in protecting against flu infection, with an immune reaction equal to or stronger than traditional needle-delivered vaccines. The patch is easy to use without medical personnel, making it ideal for developing countries.
Researchers at Rockefeller University discovered a new mechanism to create more effective and efficient vaccines against the flu virus. By harnessing modified antibodies, they were able to elicit broad protection against multiple strains of the virus.
Researchers at The Wistar Institute identified specific mutations in H3N2 viruses that made the 2014-2015 flu vaccine less effective. Antigenic drift, a phenomenon where viruses accumulate mutations to evade immune response, was found to be a key factor.
A single mutation in the H3N2 virus helped it evade the immune system's defenses, making last year's flu vaccine less effective. Researchers have identified this mutation as a key factor in the mismatch between the vaccine strain and circulating strains.
A consortium led by Massachusetts General Hospital has launched a $5.2 million project to develop an RNA-based vaccine against Q fever, a disease affecting US troops in Iraq and Afghanistan. The VaxCelerate process aims to rapidly develop vaccines for emerging infectious diseases.
A study in PLOS Medicine predicts that vaccinating Thai children with seasonal flu vaccine will reduce approximately 3,000 deaths annually. The policy is considered cost-effective according to WHO criteria.
A new study finds that measles virus has rigid surface proteins that can't tolerate mutations, making it less prone to evolution than the flu virus. This difference in protein stability may explain why measles only requires a two-dose vaccine during childhood for lifelong immunity.
Patients aged 9-26 are more likely to get HPV vaccinated after receiving reminders via electronic health records during appointments. The study found that these prompts significantly increased vaccination rates, especially among young African-American women.
A new Veterans Affairs study found that the high-dose flu vaccine provides stronger protection against flu-related hospitalizations and deaths for those 85 and older, while standard vaccines may be effective for younger seniors. The study included over 165,000 patients and tracked hospitalization and death rates.
A study by the University of Louisville found that children with neurological disorders experience a higher risk of flu complications, yet vaccination rates remain suboptimal. Parents and healthcare providers often have misconceptions about the vaccine's safety and effectiveness.
A new Ebola vaccine has been shown to be highly effective and safe in monkeys, using an experimental platform that primes the immune system with the full complement of viral proteins. The vaccine was developed by researchers at the University of Wisconsin-Madison and may offer a promising alternative to existing vaccines.
A new flu vaccine that includes four strains of inactivated influenza has been found to be more protective than a similar vaccine containing only three strains. The addition of the fourth strain increases the chance the vaccine will match the circulating flu B strains without compromising protection against other strains.
A comparative analysis by MIT researchers reveals mutations in the Indian H1N1 flu viruses that make them distinct from the 2009 vaccine strain. The study highlights the need for updated vaccination strategies to account for potential new viruses.
A team of researchers is using Twitter to gather information on vaccine refusal patterns, combining traditional survey techniques with social media analysis. The study aims to gain insights into people's reasoning about vaccines and how these reasons vary among communities.
Scientists have identified antibodies isolated from individuals with seasonal flu vaccinations that neutralize H7N9 and other influenza strains, providing broad protection. These antibodies account for a small percentage of the total immune response but show promise as potential therapeutics.
A recent study published in The Lancet found that Tamiflu significantly shortens the duration of flu symptoms by about one day and reduces respiratory infections by 44%., Researchers analyzed data from over 4,300 patients and found the drug also decreased hospital admissions by 63%.
A study found that only 54% of nursing home employees received an influenza vaccination, despite the high susceptibility of elderly residents to the virus. Inaccurate beliefs about vaccination and influenza among staff also contributed to low vaccination rates.
Joshua Plotkin, a young professor at Penn, has won the prestigious prize for his innovative theoretical work in mathematical biology. His research on the evolution of influenza virus has significant implications for public health and vaccine design.
A new analysis of human influenza B viruses sheds light on the pathogen causing seasonal flu, suggesting targeted vaccines and potential eradication of a slower-evolving lineage by expanding quadrivalent vaccine use.
Researchers at McMaster University have discovered a new class of antibodies that can neutralize a wide range of influenza A viruses, paving the way for a universal flu vaccine. The vaccine would only need to be given once and could protect against all strains of flu, even when the virus mutates.
Across Australia, severe winter temperatures are a bigger risk to health than sweltering summer heat. Death rates in cities like Brisbane were up to 30% higher in winter than summer. The study found that Australians may be more vulnerable to cold weather due to lack of preparation and focus on public health campaigns.
Researchers found that sending text message reminders increased receipt of the second dose of the vaccine by the end of the season and brought children in sooner to be vaccinated. When educational information was embedded into the text messages, the effect was even greater compared to conventional text messages or written reminders only.
A randomized controlled trial found the high-dose flu vaccine produced a stronger immune response in frail older adults living in long-term care facilities. The study suggests the high-dose vaccine may be the better option for this population to protect against flu.
A study found that the high-dose flu vaccine significantly improves immune response to flu virus in frail, older residents of long-term care facilities. The vaccine provided superior protection against laboratory-confirmed influenza illness compared to the standard vaccine.
A study found that genetic variants in the IL-28B gene affect influenza vaccine responses. Individuals with at least one copy of the minor allele were more likely to achieve seroconversion after vaccination, particularly those on high doses of immune-suppressive drugs. Blocking the IL-28B receptor may boost the antibody response to flu...
A study found that seasonal flu vaccines protect against multiple flu strains, including those not included in vaccine formulations. The researchers also discovered that exposure to birds can elicit immune responses to avian influenza viruses in humans.
A University of Florida study found that vaccinating school-aged children from flu can protect other age groups, including non-school-aged residents, with significant reductions in influenza-like illness rates. This effect is profound, both on students and the community.
A study found that seasonal flu vaccines can induce strong immune responses against multiple flu virus subtypes, including some not included in vaccine formulations. This could provide protection against emerging pandemic strains from avian populations.
A Dartmouth/Univ. of Exeter study found that correcting myths about the flu vaccine did not effectively promote immunization among vaccine skeptics, and in some cases even reduced intention to vaccinate among those with high concerns about side effects.
A systematic review found that premature birth, neurological disorders, and multiple medical conditions significantly increase the risk of hospitalization in children with influenza. The study highlights the need for clearer guidelines on which children should be prioritized for seasonal flu vaccination.
A team of researchers has discovered that 'back boosting' the immune system by pre-emptively vaccinating against likely future strains of the influenza virus can significantly improve vaccine effectiveness. This approach would allow for more targeted and effective vaccination campaigns, potentially saving millions of lives worldwide.
The Liverpool School of Tropical Medicine has been awarded two substantial grants to further develop and utilise its Experimental Human Pneumococcal Carriage (EHPC) model. The first grant, worth $2.5 million, will investigate whether a nasal spray flu vaccine alters pneumococcal carriage.
A University of Adelaide-led project has developed a new test that can identify vaccinated birds with live H5N1 virus, preventing the spread of emerging strains. This breakthrough could help track and control the highly contagious avian influenza virus.
Researchers at The Wistar Institute identified a new viral mutation that may explain why middle-aged adults were disproportionately affected by the H1N1 virus in 2013-2014. The study suggests that updating seasonal influenza vaccines with new viral strains could be crucial to protect this population.
A new study reveals how flu vaccines prevent heart attacks by stimulating the immune system to produce antibodies that protect the heart. The research identifies a protein called BKB2R as the key mechanism behind this protective effect, and suggests it could be harnessed to develop a vaccine against heart disease.
Researchers will screen tens of thousands of chemical molecules to identify effective adjuvants for vaccines against infectious diseases. The project aims to develop novel applications for enhancing the immune response against Ebola virus, HIV, and other virus infections.